arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Adaptive Biotechnologies Corp

ADPT
$27.91 ▼ -0.17 (-0.61%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
37 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Adaptive Biotechnologies Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.5B
Dividend Yield —
Revenue Growth 21.5% ↘
Op. Margin -22.0% ↗
ROIC -8.7% ↘
FCF / Share $-0.05 ↗
Trailing P/E —
Price / Book 31.1x
FCF Yield —
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Sep 23, 2026.

37-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$71.55M
↑ +21.5% —
Net Income Profit after all expenses
$-39.79M
↓ -55.3% —
Operating Margin Operating profit as % of sales
-22.0%
↑ +18.7% 10th
FCF / Share Free cash flow per share
$-0.05
↑ +28.6% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
10
Returns ↑
24
Financial Health ↑
41
Cash Quality ↓
56

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 11 years · 37 quarters